Healthcare software · Independent provider operations

Floracene

A two-person, New York based startup out of Y Combinator's Summer 2026 batch. Its own funding profile describes a tool that shows independent surgery centers the cheapest clinically equivalent implant for a procedure. Y Combinator's live company page now describes something else: a builder for HIPAA compliant internal tools. There is no independent reporting yet to referee the difference.

Two pitches, one company

Floracene has told two different stories about what it builds, and both are on the public record at once. The version behind this profile's own research file describes a purchasing tool: independent surgery centers plug in their manufacturer contracts, and the software shows the surgeon a set of clinically equivalent implants ranked by price, so a case does not default to whatever device the surgeon happens to be used to. That description also appears, largely word for word, in a third party company database entry dated September 18, 2026.

By the time this page was researched on September 25, 2026, Y Combinator's own listing for Floracene described a different product: a way for a healthcare operator to describe an internal tool in plain language and deploy it in one click, connected to production data, with access scoped by user. The two founders, the YC batch, the team size and the location are identical across both descriptions. The product is not.

The problem, as first described

The implant pitch rests on an economics argument. US surgery centers spend about $7 billion a year on implants, and in orthopedic and spine cases the implant is roughly 40 to 60 percent of the total cost of the procedure, according to the company's own account. It says roughly 20 to 30 percent of that spend is recoverable by switching to a clinically equivalent device, because more than 90 percent of expensive implants a surgeon might use are, in the company's telling, clinically interchangeable. At a hospital, the argument goes, the surgeon who picks the implant is not spending the hospital's money directly, so price does not drive the choice. At an independent center, the physicians own the economics, so a cheaper equivalent goes straight to the bottom line. Floracene's stated bet is that surgeons switch once they can see three or more equivalent options side by side, ranked against the center's actual contracts. None of this has been tested against outside data; it is the company's own account of the market, not a finding.

The pivot, as later described

The internal tools pitch rests on a different argument entirely, aimed at back office operations rather than the operating room. It says the building of software inside a healthcare business is no longer the hard part: any staff member can now describe a workflow and get an 80 percent working tool the same afternoon. What breaks, in this telling, is deployment. A tool that touches protected health information cannot go live without real authentication and permissioning, so IT blocks it, and the tool dies on the builder's own laptop. Floracene says its first customer, not named, had several employees who had each separately built useful local tools they could not share or connect to production data, and that within weeks of adopting Floracene they consolidated that tooling and shipped four new tools into production. It puts the addressable spend at about $200 billion a year on administrative software in US healthcare, with what it calls tens of thousands of companies still running core operations on spreadsheets.

The founders

Both company accounts describe the same origin story. Asaph Kupferman and Jonah Kaye met on the hospitals team at Palantir two years before founding the company, and each had spent the prior four years working in claims, eligibility and payor contracting, the company says. Asaph Kupferman is separately profiled, in a source that predates Floracene's founding, as a Data Product Manager at Garner Health with a bachelor's and master's in engineering from the University of Pennsylvania, prior work at Medtronic's diabetes group and at ZS, and a summer as a CPRIT scholar at MD Anderson Cancer Center, which is consistent with the company's account of Kupferman's healthcare background even though it does not itself mention Palantir. Jonah Kaye is listed independently as a Palantir engineer with a background in computer science and philosophy. The company says Kaye was a founding engineer at Metriport, a Y Combinator Summer 2022 company, after previously starting his own fax automation startup for fertility clinics. None of that prior work history has an independent source that names Kaye specifically at Metriport; Metriport's own team page does not list individual engineers by name.

What is proven, and what is still claimed

Read plainly: there is no public record yet that tests either version of Floracene's pitch. Everything specific to what the software does, who uses it and what it saves comes from the company itself, and the company has told two different versions of that story in the space of about a week. That is not necessarily a red flag on its own; young companies pivot, and Y Combinator listings sometimes lag or lead a company's own materials. But it means a reader cannot yet check the implant claim against a working product, because the current listing does not describe that product at all.

What to watch

• Whether Floracene settles on one product description across its own site, Y Combinator and any future press, and which of the two pitches, implant purchasing or internal tools deployment, is the one it is actually selling.
• A working, reachable floracene.com. As of this research, the live domain did not return usable content, and the only archived snapshot found predates the company's 2026 founding and shows an unrelated parked storefront page.
• A first Form D or any other SEC filing, which would be the first independent confirmation that the company has raised outside capital.
• A named customer, in either the implant purchasing or internal tools version of the business.

In their words

Related companies

• Auricle: Similar focus. A two person medical device company building an implant that stimulates the hearing nerve from outside the cochlea, so patients can gain back high frequency hearing
• Mango Medical: Similar focus. AI agents that turn a patient’s CT scan and X-rays into a surgeon-ready orthopedic surgical plan in seconds instead of days, starting with shoulder replacement
• AlgoSurg Inc: Similar focus. A Maharashtra and US company building AI software that turns a patient's CT or X-ray into a 3D surgical plan, sold as licensed technology to implant, robotics and 3D
• Zenflow: Similar focus. A small nitinol coil that props open the prostatic urethra, delivered through a flexible scope and removable at any time

Sources

1. CompanyFloracene: Vibecode + deploy HIPAA-compliant internal tools, no eng team neededY Combinator company page · accessed Sep 25, 2026
2. CompanyFloracene Funding, Complete AnalysisExtruct AI · Sep 18, 2026
3. IndependentGitHub api-evangelist/floracene, independent third party API profile stubAPI Evangelist · Jul 27, 2026
4. IndependentJonah Kaye, companies founded, co-founders and careerfounders.io · accessed Sep 25, 2026
5. IndependentWho is Asaph Kupferman? Data Product Manager and EngineerOrbit Knowledge · Mar 11, 2024
6. Public recordWayback Machine archive of floracene.com showing a parked Shopify storefront pageInternet Archive · Apr 7, 2025
7. CompanyAbout pageMetriport · accessed Sep 25, 2026
8. Public recordrecords.json research file, no FDA, trial, NIH, NSF, PubMed or Form D matches for FloraceneCompiled for this profile · Sep 25, 2026